ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
NovoCure Ltd

NovoCure Ltd (NVCR)

12.005
-0.335
( -2.71% )
Updated: 11:33:09

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
12.005
Bid
12.00
Ask
12.01
Volume
236,772
11.88 Day's Range 12.37
10.87 52 Week Range 83.60
Market Cap
Previous Close
12.34
Open
12.36
Last Trade
6
@
12
Last Trade Time
11:33:21
Financial Volume
$ 2,869,046
VWAP
12.1173
Average Volume (3m)
1,292,647
Shares Outstanding
107,093,432
Dividend Yield
-
PE Ratio
-6.18
Earnings Per Share (EPS)
-1.93
Revenue
509.34M
Net Profit
-207.04M

About NovoCure Ltd

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives it... NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Jersey, Gbr
Founded
1970
NovoCure Ltd is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NVCR. The last closing price for NovoCure was $12.34. Over the last year, NovoCure shares have traded in a share price range of $ 10.87 to $ 83.60.

NovoCure currently has 107,093,432 shares outstanding. The market capitalization of NovoCure is $1.28 billion. NovoCure has a price to earnings ratio (PE ratio) of -6.18.

NVCR Latest News

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society...

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024...

Novocure to Report First Quarter 2024 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will...

METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長

METIS臨床試験では、脳腫瘍に対する腫瘍治療電場療法(Tumor Treating Field)と支持療法を併用した患者の頭蓋内進行までの期間中央値が21.9カ月であったのに対し、支持療法のみの患者では11.3カ月であったこと...

Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs

Die METIS-Studie zeigte eine mediane Zeitspanne von 21,9 Monaten bis zur intrakraniellen Progression bei Patienten, die mit Tumor Treating Fields und Supportivtherapie behandelt wurden, im...

L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives..

L’essai METIS a montré que le délai médian avant progression intracrânienne était de 21,9 mois chez les patients traités avec la thérapie Tumor Treating Fields et des soins de support, contre...

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated...

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.045-0.37344398340212.0512.4611.7104117812.09645536CS
4-2.545-17.491408934714.5516.0511.7122735013.74679533CS
12-2.005-14.311206281214.0118.0411.7129264714.59216129CS
26-1.975-14.127324749613.9818.0410.87136719813.89276841CS
52-50.205-80.702459411762.2183.610.87151633825.08532982CS
156-196.815-94.2510295949208.82232.7610.8794427560.77446918CS
260-32.975-73.310360160144.98232.7610.8793380576.4372918CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ACONAclarion Inc
$ 0.5328
(85.00%)
70.74M
YYGHYY Group Holding Ltd
$ 3.55
(57.08%)
2.15M
BRFHBarfresh Food Group Inc
$ 1.53
(48.54%)
36.52M
SGBXSafe and Green Holdings Corporation
$ 0.21
(45.73%)
100.69M
PCSAProcessa Pharmaceuticals Inc
$ 2.26
(39.51%)
59.12M
EJHE Home Household Service Holdings Ltd
$ 0.7235
(-75.14%)
8.75M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2497
(-41.29%)
11.83M
ATNIATN International Inc
$ 19.14
(-33.36%)
106.87k
BNAIBrand Engagement Network Inc
$ 2.64
(-29.22%)
133.22k
HRYUHanryu Holdings Inc
$ 0.3727
(-29.01%)
1.06M
SGBXSafe and Green Holdings Corporation
$ 0.21
(45.73%)
100.69M
SQQQProShares UltraPro Short QQQ
$ 12.3801
(4.83%)
73.29M
ACONAclarion Inc
$ 0.5328
(85.00%)
70.74M
PCSAProcessa Pharmaceuticals Inc
$ 2.26
(39.51%)
59.12M
TSLATesla Inc
$ 165.8925
(2.32%)
55.01M

NVCR Discussion

View Posts
KIPK KIPK 3 hours ago
whosleftholdindabag - Are you da 🤡 Mate??
👍️0
KIPK KIPK 5 days ago
Gone with the wind on wings of fake therapy IMO
👍️0
KIPK KIPK 3 weeks ago
20? including a PRE-CLINICAL???? lol
And all that unfocused activity signal the total desperation to keep the SP up IMO...

Reminds me of INO, which also kept throwing stuff at every possible thing, hoping one would stick.... But NO... INO SP at one time was over $2000 & now is around $11 after a recent RS
👍️0
axelvento axelvento 3 weeks ago
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

https://www.biospace.com/article/releases/novocure-announces-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-american-association-for-cancer-research-aacr-annual-meeting-2024/
👎️ 1
TiltMyBrain TiltMyBrain 3 weeks ago
#dcvax $nwbo #gbm

Washinton State's HCA has denied coverage for Tumor Treating Fields, preventing access to this treatment option for Washington Medicaid patients and state employees.

'Optune/Tumor Treating Fields (TTF):
Petition for rereview received. Not selected for… pic.twitter.com/OPPsTyjXhk— Peter Davis (@peter_brit) April 2, 2024

This ship is sinking fast!
👍️ 2 👏 2
TiltMyBrain TiltMyBrain 4 weeks ago
insider selling in 3...2...1...
👍️ 2 💯 2 😂 1 🤣 1
TiltMyBrain TiltMyBrain 4 weeks ago
"Preliminary analyses of key secondary endpoints (time to neurocognitive failure, overall survival, and radiological response rate) did not demonstrate statistical significance."

pump and dump in progress
👍️ 1 💯 1 🤡 1 🤣 1
whosleftholdindabag whosleftholdindabag 4 weeks ago
Loving the early action on $NVCR. Wishing everybody a great day! GLTA
🗑️ 1 🤣 2
KIPK KIPK 4 weeks ago
LOL - "In time to Intracranial Progression" ??? SMH
💩 1 🖕 1
Awl416 Awl416 4 weeks ago
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
👍️ 2 💯 1
KIPK KIPK 1 month ago
The Vanishing tin can on the wind of ineffectiveness!!
Have a kick at it MATE - LOL !!
💩 1 🖕 1
KIPK KIPK 1 month ago
You just made a positive post for NWBO without knowing it MATE. Think JAMA.....

And that's So sad as You must be in total loss for words to be citing here a post by a Paid NWBO Basher, InquiriNg. At least you should have given the credit as she, just like you, has been lost for words as well MATE!! . LOL Mate!!

You Birt got nothing & the tin hat is made for a tin man... just like you & the charity investor scamwannabe!!
LOL
👍️ 2 💩 1 🖕 1 🤣 1
jondoeuk jondoeuk 1 month ago
NWBO's DCVax-L is an expensive placebo. The same is true for DCVax-Direct.
👍️ 1 💯 1 🗑️ 2 🤮 1 ❌️ 1
KIPK KIPK 1 month ago
Congrats whosbagholding. You keep expanding your reach into Charity Work. LOL - SMH...

Below is a response to one of your good will intention (LOL) on NWBO MB>>>>
Re: AAPL31415926 post# 679357

Monday, March 18, 2024 8:40:02 AM

Post#
679360
of 679363
Amazing that whosbagholding gave me a clown emoji on this comment. It shows how absolutely evil these people are. Hopefully he/she/it/they don't have to face their spouse or one of their children being diagnosed with a fatal disease that they work hard to try and destroy a cure for. Then again there's always karma.
💩 1 🖕 1
KIPK KIPK 2 months ago
Who S Left Hold In D Bag - LOL LOL LOL LOL - Brit Mate?? LOL
👍️ 1 💩 1 🖕 1 🤣 1
KIPK KIPK 2 months ago
Anyone looking for, whosleftholdindabag, the fake charity worker mate (lol), he spends all his time on NWBO MB, fingering up 🖕🏻 (LOL), NWBO paid bashers.
This dude is full of undigested charity food (LOL)
👍️ 1 💥 1 💩 1 🖕 1 😂 1 🤣 1
KIPK KIPK 2 months ago
whosleftholdindabag - LOL, LOL, LOL< LOL👎🏻🤢
👍️ 1 💥 1
KIPK KIPK 2 months ago
whosleftholdindabag - This thing must TOTALLY Believe Survival of NVCR, that he claims invested in for charity, TOTALLY Depends on Death of NWBO, Otherwise why Spending all hours on NWBO MB, supporting NWBO Bashers, while giving 👎🏻 / 🤡 to NWBO Longs???

A charitable character would innately support all companies who are trying to do good & and be a positive difference maker in peoples life! I guess that description is contrary to his motives!!
👍️ 2 💯 1
KIPK KIPK 2 months ago
Poor resentful LOSER....
Rent Free, LOL... I just hate pretenders like you ... MATE?? LOL///
Like lurking Junk yard dog.... as you are..
Bloody Bitter?? who uses that term... ??
Dummy Englishio??
Woof Woof Woof...
Bugger off??? LOL --- How old are you? 100? LOL
👍️ 2 🤣 1
whosleftholdindabag whosleftholdindabag 2 months ago
Why are you so bloody bitter mate? I live rent-free in your head, find a hobby, get a job, and do something useful with your life!

It's a shame about Dr. B. I thought he was a good bloke.

Go back to your other obsession, $NWBO and bugger off!
👍️ 1 💩 1 🤢 1
KIPK KIPK 2 months ago
Hey, whosleftholdindabag. Who is Holding That Big, Fat, Bag?? The Fake Tech is declaring its Fakeness IMO...
Keep adding now!!
👍️ 1 🤣 1
KIPK KIPK 2 months ago
Fake charity investor, whosleftholdindabag, keep lucking around NWBO MB, giving thumbs up to known trash or cash posters & thumbs down to reputable/knowledgeable NWBO investors..

What a waste of a life... SMH
👍️ 1 💩 1 💯 1 🖕 1
dennisdave dennisdave 3 months ago
sure click on the link https://investorshub.advfn.com/boards/replies.aspx?msg=173765065
take the mouse from your mom's computer and move the mouse pointer on your screen (so not the actual mouse in your hand but the one on the screen) to the link (the link is in blue in the post). Click the right button on the mouse in your hand to open the link. Then reread the post. If you dont understand these instructions ask a caregiver to help you.
💩 1 🤢 1
KIPK KIPK 3 months ago
Its so, so, so incredible therapy that its MB see all read/// LOL
💩 1 🖕 1
KIPK KIPK 3 months ago
The poor & Desperate, whosleftholdindabag, spends all his time giving thumbs up supports to any who posts something negative about NWBO, SMH...

What a pretend BS...
💩 1 🖕 1
KIPK KIPK 3 months ago
whoseletholdingabag... LOL.. & LOL big time at you... NVCR is stuck here until it goes to sub1$
💩 1 🖕 1
KIPK KIPK 3 months ago
bottomless pit because the stuff doesn't work as advertised IMO
💩 1 🖕 1
KIPK KIPK 3 months ago
NOoooo, junkoeuk,,,, The NoCure Signals were twisted from the get go.... game over now that the cat out of the hat finally IMO... da update, da rev. no matter what you post... Fact has this down from over 200 to about $10,,, dat should tell you some fact!! LOLing,,,,
👍️ 1 💯 1
jondoeuk jondoeuk 3 months ago
TRIDENT update https://www.businesswire.com/news/home/20240109397768/en/Novocure-Announces-Last-Patient-Enrolled-in-Phase-3-TRIDENT-Trial-in-Newly-Diagnosed-Glioblastoma
👎🏻 1
jondoeuk jondoeuk 3 months ago
Full Year and Fourth Quarter '23 Net Revenues and Company Update https://finance.yahoo.com/news/novocure-announces-preliminary-full-fourth-120000184.html
👍️ 1 👎🏻 1
KIPK KIPK 4 months ago
NoCure Trapping More INVESTORS IMO.. This thing not worth considering at all IMO,,,
A treading stock for those skilled to do it IMO..
💩 1 🖕 1
jondoeuk jondoeuk 4 months ago
Upcoming https://www.biospace.com/article/releases/novocure-to-participate-in-42nd-annual-j-p-morgan-healthcare-conference/
👍️ 1 👎🏻 1
dstock07734 dstock07734 4 months ago
He used to be silent. At most, he just liked some of the posts by his minions to remind them: Big brother is watching.

The fact he broke silence all of sudden shows how desperate he is now with the latest PR from NWBO. 2024 is not going to be lovely for him.
👍️ 1 💥 1
KIPK KIPK 4 months ago
Fake Charity Contributor. Keep Bashing NWBO!! LOL. what nobody!!
👍️ 1
KIPK KIPK 4 months ago
And the Charity Bag-holder sounds BLOODY BRITSH .. LOL, you “IS” truly A BLOODY LOSER.
Go get some crisp in used newspapers rapping!!!
Lol
👍️ 1 💥 1
KIPK KIPK 4 months ago
Whosleleftholeindabag. You must be the worse manipulator as a charity investor. A charitable being does NOT go to other company MB & posts trash, hoping that company, NWBO, would fail, so that NVCR, you keep claiming you invested in for charity, would win!!

Dude, you are the worst among the manipulating worst I have encounter.
Just think KARMA.

What a loser.. LOL!!
👍️ 1 💥 1
whosleftholdindabag whosleftholdindabag 4 months ago
A lovely way to close out 2023! Go $NVCR we're going to raise a lot of money for charity! GLTA
👿 1 🤮 1
TiltMyBrain TiltMyBrain 4 months ago
Desperation for sure
👍️ 3
KIPK KIPK 4 months ago
And NoCure is firing staff. Then this loser claiming he is adding AGAIN & AGAIN & AGAIN...

Delusional? or Manipulator?
👍️ 3 💩 1 🖕 1
TiltMyBrain TiltMyBrain 4 months ago
Northwest Bio files for mhra approval

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html

NVCR is toast!
👍️ 4 💥 3 🤡 2
whosleftholdindabag whosleftholdindabag 5 months ago
Another 25k share purchase $NVCR. The company is serious about controlling costs! Probably my last purchase this year. GLTA
💩 2 🖕🏻 3 🤡 2
TiltMyBrain TiltMyBrain 5 months ago
This ship is sinking fast!
👍️0
KIPK KIPK 5 months ago
On this thanksgiving day, Whosleftholdindabag, the Self Proclaimed Charity Investor, spending his charity day
supporting the well know NWBO paid basher LC2020......

Dude you have set a very high standards for yourself!!! LOL

KAMA looking you in the EYE!!!!
👍️ 1 🖕🏻 1 🤮 1
KIPK KIPK 5 months ago
whosleftholdindabag is Left Giving Thumbs Down to NWBO investors on its MB... What a fake charity supporting loser!!

KARMA looking into your EYE!!
💩 1 🤮 1
KIPK KIPK 5 months ago
Its time for a bigger bag for whoslefthHOLDINGdaBG...... Bag holder!! go to it now!!

LOL
🤣 1 🤮 1
dstock07734 dstock07734 5 months ago
Please read the two posters from Dr. Liau. Then you probably have a good idea on the significance of TCR sequencing. You probably also understand why Merck had collaboration with those Next Generation Sequencing companies as early as 2015.



👍️ 1 💥 1
dstock07734 dstock07734 5 months ago
Is it so hard to embrace the future? NVCR is sinking and you know it.

Here is the future.

https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v64/7405465?redirectedFrom=fulltext#no-access-message

T CELL RESPONSE DYNAMICS IN PHASE 3 GLIOBLASTOMA PATIENTS IMMUNIZED WITH AUTOLOGOUS DENDRITIC CELLS PULSED WITH AUTOLOGOUS TUMOR CELL LYSATE

BACKGROUND

331 glioblastoma patients were immunized with autologous dendritic cells (DCs) pulsed with autologous tumor cell lysate or placebo in a Phase 3 clinical trial. Immunization with the pulsed DCs was associated with extended overall survival in both newly diagnosed and recurrent disease. Objective: To characterize T cell responses and T cell response dynamics in patients immunized with autologous dendritic cells pulsed with autologous tumor cell lysate.

METHODS

we performed T cell receptor sequencing on peripheral blood mononuclear cells from both newly diagnosed and recurrent glioblastoma patients that were treated with the pulsed DCs. Timepoints from both before and after immunization were compared to understand T cell response dynamics.

RESULTS

Expansion of several hundred new T cell clones as well as more than 700 previously detected T cell clones was detected over time in both newly diagnosed and recurrent GBM patients who were treated with the pulsed DCs. Investigation of the dynamics of the response demonstrated that further expansion was triggered by ongoing immunizations. Correlations between T cell response data and clinical outcomes are ongoing.

CONCLUSION

Immunization with autologous DCs pulsed with autologous tumor cell lysate induces broad spectrum immune responses in patients with glioblastoma.
👍️ 1 💥 1
jondoeuk jondoeuk 5 months ago
The abstracts

https://jitc.bmj.com/content/11/Suppl_1/A661

https://jitc.bmj.com/content/11/Suppl_1/A691

https://jitc.bmj.com/content/11/Suppl_1/A1189
💩 1 🖕🏻 1
TiltMyBrain TiltMyBrain 6 months ago
Single digits on the way
👍️0
Garyedward71 Garyedward71 6 months ago
Or they know something we already know.
👍️0

Your Recent History

Delayed Upgrade Clock